NASDAQ:WVE Wave Life Sciences (WVE) Stock Price, News & Analysis → “The Stock Market’s Bull Run is Far from Over” -Barrons (From Vertical Research Advisory) (Ad) Free WVE Stock Alerts $6.17 +0.13 (+2.15%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$5.89▼$6.1850-Day Range$3.54▼$6.8452-Week Range$3.15▼$7.67Volume596,534 shsAverage Volume936,741 shsMarket Capitalization$754.47 millionP/E RatioN/ADividend YieldN/APrice Target$9.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Wave Life Sciences alerts: Email Address Wave Life Sciences MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.71 Rating ScoreUpside/Downside45.9% Upside$9.00 Price TargetShort InterestHealthy2.45% of Shares Sold ShortDividend StrengthN/ASustainability-0.58Upright™ Environmental ScoreNews Sentiment1.20Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.94) to ($1.07) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.57 out of 5 starsMedical Sector98th out of 938 stocksPharmaceutical Preparations Industry35th out of 423 stocks 3.4 Analyst's Opinion Consensus RatingWave Life Sciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on 5 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $9.00, Wave Life Sciences has a forecasted upside of 45.9% from its current price of $6.17.Amount of Analyst CoverageWave Life Sciences has only been the subject of 2 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted2.45% of the outstanding shares of Wave Life Sciences have been sold short.Short Interest Ratio / Days to CoverWave Life Sciences has a short interest ratio ("days to cover") of 3.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Wave Life Sciences has recently increased by 0.67%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldWave Life Sciences does not currently pay a dividend.Dividend GrowthWave Life Sciences does not have a long track record of dividend growth. Previous Next 4.8 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreWave Life Sciences has received a 77.37% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Preclinical research services for physical health", "Clinical research services for physical health", and "Basic medical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Wave Life Sciences is -0.58. Previous Next 4.0 News and Social Media Coverage News SentimentWave Life Sciences has a news sentiment score of 1.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Wave Life Sciences this week, compared to 2 articles on an average week.Search Interest6 people have searched for WVE on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.MarketBeat Follows5 people have added Wave Life Sciences to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Wave Life Sciences insiders have not sold or bought any company stock.Percentage Held by Insiders31.10% of the stock of Wave Life Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions89.73% of the stock of Wave Life Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Wave Life Sciences are expected to decrease in the coming year, from ($0.94) to ($1.07) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Wave Life Sciences is -11.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Wave Life Sciences is -11.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioWave Life Sciences has a P/B Ratio of 15.43. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Vertical Research Advisory“The Stock Market’s Bull Run is Far from Over” -BarronsBarron's reports that the "stock market's bull run is FAR from over…" And recent economic growth will fuel the price of select stocks in the coming months!Click here for all the details now… About Wave Life Sciences Stock (NASDAQ:WVE)Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; siRNA clinical candidate for the treatment of obesity and other metabolic disorders; WVE-N531, a exon skipping oligonucleotide for the treatment of duchenne muscular dystrophy; and WVE-003, an antisense silencing oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore.Read More WVE Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart WVE Stock News HeadlinesMarch 27, 2024 | globenewswire.comWave Life Sciences to Present at Upcoming Investor ConferencesMarch 23, 2024 | finance.yahoo.comBillionaire Paul Tudor Jones and Insiders Love These 10 StocksMarch 29, 2024 | Vertical Research Advisory (Ad)“The Stock Market’s Bull Run is Far from Over” -BarronsBarron's reports that the "stock market's bull run is FAR from over…" And recent economic growth will fuel the price of select stocks in the coming months!March 15, 2024 | msn.comWind and wave observations reveal the seasonal variations in wave-induced stress over global oceanMarch 9, 2024 | finance.yahoo.comWave Life Sciences Ltd. (NASDAQ:WVE) Reported Earnings Last Week And Analysts Are Already Upgrading Their EstimatesMarch 8, 2024 | seekingalpha.comWave Life Sciences' Weighty Ambition: Carving Out Obesity NicheMarch 8, 2024 | seekingalpha.comWave Life Sciences Ltd. (WVE) Q4 2023 Earnings Call TranscriptMarch 7, 2024 | finance.yahoo.comWave Life Sciences Ltd. (NASDAQ:WVE) Q4 2023 Earnings Call TranscriptMarch 29, 2024 | Vertical Research Advisory (Ad)“The Stock Market’s Bull Run is Far from Over” -BarronsBarron's reports that the "stock market's bull run is FAR from over…" And recent economic growth will fuel the price of select stocks in the coming months!March 6, 2024 | marketwatch.comWave Life Sciences Shares Rise 31% After Narrower-Than-Expected 4Q LossMarch 6, 2024 | msn.comWave Life Sciences GAAP EPS of -$0.15 beats by $0.08, revenue of $29.06M beats by $9.23MMarch 6, 2024 | washingtonpost.comWave Life Sciences: Q4 Earnings SnapshotMarch 6, 2024 | markets.businessinsider.comWave Life Sciences Gains 34% On Narrower Loss In Q4March 6, 2024 | globenewswire.comWave Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateMarch 5, 2024 | msn.comWave Life Sciences Q4 2023 Earnings PreviewMarch 2, 2024 | finance.yahoo.comWave Life Sciences Ltd. (WVE)February 28, 2024 | globenewswire.comWave Life Sciences Fourth Quarter and Full Year 2023 Financial Results Scheduled for March 6, 2024February 27, 2024 | msn.comWas the 100 Foot Wave Surfed? A Semi-Scientific Breakdown (Clip)February 27, 2024 | globenewswire.comWave Life Sciences Announces Upcoming Presentations at MDA Conference that Highlight Best-in-Class Potential for WVE-N531 in Duchenne Muscular DystrophyFebruary 24, 2024 | yahoo.com10-Foot Wave Explodes on Surfer's Head, Friends Nearly Call 911 (Clip)February 23, 2024 | yahoo.comThriller at Killers: Big Wave Surfers Ride 30-Foot Waves in Specialty Mexico ContestFebruary 23, 2024 | yahoo.comBig Wave Surfer Kai Lenny Reveals 'Trick' to Surviving 60-Foot WavesFebruary 22, 2024 | news.yahoo.comGalactic Wave May Have Crossed Paths With Earth, Scientists FindFebruary 6, 2024 | yahoo.comWatch Now: “The Longest Wave in Africa”January 23, 2024 | finance.yahoo.comThe past five years for Wave Life Sciences (NASDAQ:WVE) investors has not been profitableJanuary 11, 2024 | markets.businessinsider.comLeerink Partners Sticks to Its Buy Rating for Wave Life Sciences (WVE)January 8, 2024 | finance.yahoo.comWave Life Sciences Highlights Recent Achievements and Upcoming 2024 MilestonesSee More Headlines Receive WVE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Wave Life Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/06/2024Today3/28/2024Next Earnings (Estimated)5/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:WVE CUSIPN/A CIK1631574 Webwww.wavelifesciences.com Phone(656) 236-3388Fax617-949-2901Employees266Year FoundedN/APrice Target and Rating Average Stock Price Target$9.00 High Stock Price Target$15.00 Low Stock Price Target$5.00 Potential Upside/Downside+50.3%Consensus RatingModerate Buy Rating Score (0-4)2.71 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($0.55) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-57,510,000.00 Net Margins-50.76% Pretax Margin-51.36% Return on EquityN/A Return on Assets-23.67% Debt Debt-to-Equity RatioN/A Current Ratio1.26 Quick Ratio1.26 Sales & Book Value Annual Sales$113.31 million Price / Sales6.46 Cash FlowN/A Price / Cash FlowN/A Book Value$0.40 per share Price / Book14.98Miscellaneous Outstanding Shares122,280,000Free Float84,254,000Market Cap$732.46 million OptionableOptionable Beta-1.16 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesDr. Paul B. Bolno M.B.A. (Age 50)M.D., President, CEO & Director Comp: $1.1MMr. Kyle B. Moran CFA (Age 53)CFO & Principal Accounting Officer Comp: $677.87kDr. Chandra Vargeese Ph.D. (Age 63)Chief Technology Officer Comp: $710.05kKate RauschHead of Investor RelationsMs. Linda Rockett J.D.Senior VP & General CounselDr. Christopher Francis Ph.D. (Age 46)Senior VP of Corporate Development & Head of Emerging Areas Comp: $493.13kMs. Daryn LewisSenior VP & Head of Human ResourcesDr. Sridhar Vaddeboina Ph.D.Senior Vice President of Chemistry, Manufacturing & ControlsMs. Anne-Marie Li-Kwai-CheungChief Development OfficerDr. Hsiu-Chiung Yang Ph.D.Senior Vice President of Translational MedicineMore ExecutivesKey CompetitorsY-mAbs TherapeuticsNASDAQ:YMABOPKO HealthNASDAQ:OPKSavaraNASDAQ:SVRAApplied TherapeuticsNASDAQ:APLTAerovate TherapeuticsNASDAQ:AVTEView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 129,823 shares on 3/11/2024Ownership: 1.073%Wellington Management Group LLPBought 9,208 shares on 3/5/2024Ownership: 0.277%Goldman Sachs Group Inc.Bought 49,338 shares on 3/1/2024Ownership: 0.395%Virtu Financial LLCBought 34,432 shares on 2/26/2024Ownership: 0.035%Public Employees Retirement System of OhioBought 12,600 shares on 2/16/2024Ownership: 0.013%View All Insider TransactionsView All Institutional Transactions WVE Stock Analysis - Frequently Asked Questions Should I buy or sell Wave Life Sciences stock right now? 7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Wave Life Sciences in the last twelve months. There are currently 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" WVE shares. View WVE analyst ratings or view top-rated stocks. What is Wave Life Sciences' stock price target for 2024? 7 Wall Street research analysts have issued twelve-month price objectives for Wave Life Sciences' stock. Their WVE share price targets range from $5.00 to $15.00. On average, they anticipate the company's stock price to reach $9.00 in the next twelve months. This suggests a possible upside of 45.9% from the stock's current price. View analysts price targets for WVE or view top-rated stocks among Wall Street analysts. How have WVE shares performed in 2024? Wave Life Sciences' stock was trading at $5.05 at the beginning of the year. Since then, WVE stock has increased by 22.2% and is now trading at $6.17. View the best growth stocks for 2024 here. When is Wave Life Sciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024. View our WVE earnings forecast. How were Wave Life Sciences' earnings last quarter? Wave Life Sciences Ltd. (NASDAQ:WVE) announced its quarterly earnings data on Wednesday, March, 6th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.19) by $0.04. The firm had revenue of $29.06 million for the quarter, compared to analyst estimates of $23.30 million. During the same quarter last year, the company earned ($0.47) earnings per share. What ETF holds Wave Life Sciences' stock? iShares Neuroscience and Healthcare ETF holds 8,533 shares of WVE stock, representing 0.84% of its portfolio. What is Paul Bolno, M.D., MBA's approval rating as Wave Life Sciences' CEO? 17 employees have rated Wave Life Sciences Chief Executive Officer Paul Bolno, M.D., MBA on Glassdoor.com. Paul Bolno, M.D., MBA has an approval rating of 92% among the company's employees. This puts Paul Bolno, M.D., MBA in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Wave Life Sciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Wave Life Sciences investors own include Gilead Sciences (GILD), Exelixis (EXEL), Sangamo Therapeutics (SGMO), Sorrento Therapeutics (SRNE), TherapeuticsMD (TXMD), VBI Vaccines (VBIV), Aduro Biotech (ADRO), Cidara Therapeutics (CDTX), CRISPR Therapeutics (CRSP) and ImmunoGen (IMGN). Who are Wave Life Sciences' major shareholders? Wave Life Sciences' stock is owned by many different retail and institutional investors. Top institutional investors include M28 Capital Management LP (7.44%), Primecap Management Co. CA (3.80%), Point72 Asset Management L.P. (3.24%), Price T Rowe Associates Inc. MD (1.64%), Price T Rowe Associates Inc. MD (1.64%) and Vanguard Group Inc. (1.33%). Insiders that own company stock include Chandra Vargeese, Chris Francis, Kyle Moran, Paul Bolno and Ra Capital Management, LP. View institutional ownership trends. How do I buy shares of Wave Life Sciences? Shares of WVE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:WVE) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeGrab Your Free Bitcoin Today!Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 Media“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyFed launches fourth dollar overhaulStansberry ResearchAI healthcare stock poised for 36,996% growth?Behind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Wave Life Sciences Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.